Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts

Journal of Experimental Medicine

Volumn 207, Issue 3, 2010, Pages 637-650

  Quezada, Sergio A ^a   Simpson, Tyler R ^a   Peggs, Karl S ^a   Merghoub, Taha ^a   Vider, Jelena ^a   Fan, Xiaozhou ^a   Blasberg, Ronald ^a   Yagita, Hideo ^b   Muranski, Pawel ^c   Antony, Paul A ^d   Restifo, Nicholas P ^c   Allison, James P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; IA ANTIBODY; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TYROSINASE RELATED PROTEIN 1;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RISK; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTOPENIA; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL DIVISION; DISEASE MODELS, ANIMAL; INTERFERON-GAMMA; LEUKEMIA, T-CELL; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES, CYTOTOXIC; TRYPSIN;

EID: 77949522803     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20091918     Document Type: Article

References (49)

1. Antony, P.A., C.A. Piccirillo, A. Akpinarli, S.E. Finkelstein, P.J. Speiss, D.R. Surman, D.C. Palmer, C.C. Chan, C.A. Klebanoff, W.W. Overwijk, et al. 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174:2591-2601.
2. Blair, D.A., and L. Lefrançois. 2007. Increased competition for antigen during priming negatively impacts the generation of memory CD4 T cells. Proc. Natl. Acad. Sci. USA. 104:15045-15050. doi:10.1073/pnas.0703767104
3. Boehm, U., T. Klamp, M. Groot, and J.C. Howard. 1997. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:749-795. doi:10.1146/annurev. immunol.15.1.749
4. Boss, J.M. 1997. Regulation of transcription of MHC class II genes. Curr. Opin. Immunol. 9:107-113. doi:10.1016/S0952-7915(97)80166-5
5. Burns, W.R., Z. Zheng, S.A. Rosenberg, and R.A. Morgan. 2009. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood. 114:2888-2899.
6. Corthay, A. 2007. CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells. Adv. Exp. Med. Biol. 590:195-208. doi:10.1007/978-0-387-34814-8-14
7. Corthay, A., D.K. Skovseth, K.U. Lundin, E. Røsjø, H. Omholt, P.O. Hofgaard, G. Haraldsen, and B. Bogen. 2005. Primary antitumor immune response mediated by CD4+ T cells. Immunity. 22:371-383. doi:10.1016/j.immuni.2005.02.003
8. Dudley, M.E., J.R. Wunderlich, P.F. Robbins, J.C. Yang, P. Hwu, D.J. Schwartzentruber, S.L. Topalian, R. Sherry, N.P. Restifo, A.M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850-854. doi:10.1126/science. 1076514
9. Dudley, M.E., J.C. Yang, R. Sherry, M.S. Hughes, R. Royal, U. Kammula, P.F. Robbins, J. Huang, D.E. Citrin, S.F. Leitman, et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26:5233-5239. doi:10.1200/JCO.2008.16.5449
10. Ganss, R., E. Ryschich, E. Klar, B. Arnold, and G.J. Hämmerling. 2002. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62:1462-1470.
11. + T cells. J. Exp. Med. 202:907-912. doi:10.1084/jem.20050732
12. Gattinoni, L., C.A. Klebanoff, D.C. Palmer, C. Wrzesinski, K. Kerstann, Z. Yu, S.E. Finkelstein, M.R. Theoret, S.A. Rosenberg, and N.P. Restifo. 2005b. Acquisition of full effector function in vitro paradoxically imon pairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115:1616-1626. doi:10.1172/JCI24480
13. Gattinoni, L., X.S. Zhong, D.C. Palmer, Y. Ji, C.S. Hinrichs, Z. Yu, C. Wrzesinski, A. Boni, L. Cassard, L.M. Garvin, et al. 2009. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15:808-813.
14. Gonzalez, M., S.A. Quezada, B.R. Blazar, A. Panoskaltsis-Mortari, A.Y. Rudensky, and R.J. Noelle. 2002. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning. J. Immunol. 169:5581-5589.
15. - T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161:1122-1134. doi:10.1084/jem.161.5.1122
16. Hanson, H.L., D.L. Donermeyer, H. Ikeda, J.M. White, V. Shankaran, L.J. Old, H. Shiku, R.D. Schreiber, and P.M. Allen. 2000. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity. 13:265-276. doi:10.1016/S1074-7613(00)00026-1
17. Hataye, J., J.J. Moon, A. Khoruts, C. Reilly, and M.K. Jenkins. 2006. Naive and memory CD4+ T cell survival controlled by clonal abundance. Science. 312:114-116. doi:10.1126/science.1124228
18. + CTL. J. Exp. Med. 202:1109-1119. doi:10.1084/jem.20050162
19. + T cells: ready for direct attack. J. Exp. Med. 203:805-808. doi:10.1084/jem.20060215
20. Holloway, P.A., N. Kaldenhoven, H.M. Kok-Schoemaker, M. Dijk, H.G. Otten, M. Tilanus, S. Postma, T. Mutis, H.M. Lokhorst, and A.C. Bloem. 2005. A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution. Br. J. Haematol. 128:73-81. doi:10.1111/j.1365-2141.2004.05283.x
21. Hunder, N.N., H. Wallen, J. Cao, D.W. Hendricks, J.Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J.A. Thompson, and C. Yee. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358:2698-2703. doi:10.1056/NEJMoa0800251
22. + T cells in the antitumor immune response. J. Exp. Med. 188:2357-2368. doi:10.1084/jem.188.12.2357
23. June, C.H. 2007. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 117:1466-1476. doi:10.1172/JCI32446
24. Lee, Y.K., H. Turner, C.L. Maynard, J.R. Oliver, D. Chen, C.O. Elson, and C.T. Weaver. 2009. Late developmental plasticity in the T helper 17 lineage. Immunity. 30:92-107. doi:10.1016/j.immuni.2008.11.005
25. Lugade, A.A., J.P. Moran, S.A. Gerber, R.C. Rose, J.G. Frelinger, and E.M. Lord. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174:7516-7523.
26. Martin-Orozco, N., Y. Chung, S.H. Chang, Y.H. Wang, and C. Dong. 2009. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur. J. Immunol. 39:216-224. doi:10.1002/eji.200838475
27. Morgan, R.A., M.E. Dudley, J.R. Wunderlich, M.S. Hughes, J.C. Yang, R.M. Sherry, R.E. Royal, S.L. Topalian, U.S. Kammula, N.P. Restifo, et al. 2006. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 314:126-129. doi:10.1126/science.1129003
28. Mumberg, D., P.A. Monach, S. Wanderling, M. Philip, A.Y. Toledano, R.D. Schreiber, and H. Schreiber. 1999. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA. 96:8633-8638. doi:10.1073/pnas.96.15.8633
29. Muranski, P., and N.P. Restifo. 2009. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr. Opin. Immunol. 21:200-208. doi:10.1016/j.coi.2009.02.004
30. Muranski, P., A. Boni, C. Wrzesinski, D.E. Citrin, S.A. Rosenberg, R. Childs, and N.P. Restifo. 2006. Increased intensity lymphodepletion and adoptive immunotherapy-how far can we go? Nat. Clin. Pract. Oncol. 3:668-681. doi:10.1038/ncponc0666
31. Muranski, P., A. Boni, P.A. Antony, L. Cassard, K.R. Irvine, A. Kaiser, C.M. Paulos, D.C. Palmer, C.E. Touloukian, K. Ptak, et al. 2008. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 112:362-373. doi:10.1182/blood-2007-11-120998
32. + T cells. J. Exp. Med. 198:569-580. doi:10.1084/jem.20030590
33. Paludan, C., K. Bickham, S. Nikiforow, M.L. Tsang, K. Goodman, W.A. Hanekom, J.F. Fonteneau, S. Stevanovi?, and C. Münz. 2002. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 169:1593-1603.
34. Pardoll, D.M., and S.L. Topalian. 1998. The role of CD4+ T cell responses in antitumor immunity. Curr. Opin. Immunol. 10:588-594. doi:10.1016/S0952-7915(98)80228-8
35. Peggs, K.S., S.A. Quezada, A.J. Korman, and J.P. Allison. 2006. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr. Opin. Immunol. 18:206-213.
36. Peggs, K.S., S.A. Quezada, C.A. Chambers, A.J. Korman, and J.P. Allison. 2009. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206:1717-1725.
37. Perez-Diez, A., N.T. Joncker, K. Choi, W.F. Chan, C.C. Anderson, O. Lantz, and P. Matzinger. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood. 109:5346-5354. doi:10.1182/blood-2006- 10-051318
38. Pollock, P.M., K. Cohen-Solal, R. Sood, J. Namkoong, J.J. Martino, A. Koganti, H. Zhu, C. Robbins, I. Makalowska, S.S. Shin, et al. 2003. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat. Genet. 34:108-112. doi:10.1038/ng1148
39. Quezada, S.A., K.S. Peggs, M.A. Curran, and J.P. Allison. 2006. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116:1935-1945. doi:10.1172/JCI27745
40. Quezada, S.A., K.S. Peggs, T.R. Simpson, Y. Shen, D.R. Littman, and J.P. Allison. 2008. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205:2125-2138. doi:10.1084/jem. 20080099
41. Rapoport, A.P., E.A. Stadtmauer, N. Aqui, A. Badros, J. Cotte, L. Chrisley, E. Veloso, Z. Zheng, S. Westphal, R. Mair, et al. 2005. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11:1230-1237. doi:10.1038/nm1310
42. + T cell precursor frequency determines the quality of the antitumor immune response. J. Exp. Med. 206:849-866. doi:10.1084/jem.20081382
43. Shi, G., C.A. Cox, B.P. Vistica, C. Tan, E.F. Wawrousek, and I. Gery. 2008. Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. J. Immunol. 181:7205-7213.
44. Spaapen, R.M., H.M. Lokhorst, K. van den Oudenalder, B.E. Otterud, H. Dolstra, M.F. Leppert, M.C. Minnema, A.C. Bloem, and T. Mutis. 2008. Toward targeting B cell cancers with CD4+ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genomewide analysis. J. Exp. Med. 205:2863-2872. doi:10.1084/jem.20080713
45. Spiotto, M.T., D.A. Rowley, and H. Schreiber. 2004. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10:294-298. doi:10.1038/nm999
46. Wu, Z., P.A. Biro, R. Mirakian, L. Hammond, F. Curcio, F.S. Ambesi-Impiombato, and G.F. Bottazzo. 1999. HLA-DMB expression by thyrocytes: indication of the antigen-processing and possible presenting capability of thyroid cells. Clin. Exp. Immunol. 116:62-69. doi:10.1046/j.1365-2249. 1999.00831.x
47. Wu, Z., P.A. Biro, R. Mirakian, F. Curcio, F.S. Ambesi-Impiombato, and G.F. Bottazzo. 2000. Transcriptional regulation of the MHC II gene DRA in untransformed human thyrocytes. Int. Immunol. 12:405-413. doi:10.1093/intimm/12.4.405
48. Yee, C., J.A. Thompson, D. Byrd, S.R. Riddell, P. Roche, E. Celis, and P.D. Greenberg. 2002. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA. 99:16168-16173. doi:10.1073/pnas.242600099
49. Zhang, B., N.A. Bowerman, J.K. Salama, H. Schmidt, M.T. Spiotto, A. Schietinger, P. Yu, Y.X. Fu, R.R. Weichselbaum, D.A. Rowley, et al. 2007. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204:49-55. doi:10.1084/jem.20062056